TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 261-272

  Simmons, John K ^a   Patel, Jyoti ^a   Michalowski, Aleksandra ^a   Zhang, Shuling ^a   Wei, Bih Rong ^a   Sullivan, Patrick ^a   Gamache, Ben ^a   Felsenstein, Kenneth ^a   Kuehl, W Michael ^a   Simpson, R Mark ^a   Zingone, Adriana ^a   Landgren, Ola ^a   Mock, Beverly A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Burkitt's lymphoma; Entinostat; Mantle cell lymphoma; Myeloma; Plasmacytoma; Siroliumus

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ENTINOSTAT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL XL; RAPAMYCIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL MATURATION; CELL SURVIVAL; COCULTURE; DRUG POTENTIATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TUMOR MICROENVIRONMENT; CONTROLLED STUDY; MULTIPLE MYELOMA; PLASMACYTOMA;

BURKITT'S LYMPHOMA; ENTINOSTAT; MANTLE CELL LYMPHOMA; MYELOMA; PLASMACYTOMA; SIROLIUMUS;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, NUDE; MULTIPLE MYELOMA; MULTIPROTEIN COMPLEXES; PLASMACYTOMA; PYRIDINES; TOR SERINE-THREONINE KINASES;

EID: 84894350310     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.11.007     Document Type: Article

References (70)

1. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., Dave S., Hurt E.M., Tan B., Zhao H., Stephens O., Santra M., Williams D.R., Dang L., Barlogie B., Shaughnessy J.D., Kuehl W.M., Staudt L.M. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
2. Annunziata C.M., Hernandez L., Davis R.E., Zingone A., Lamy L., Lam L.T., Hurt E.M., Shaffer A.L., Kuehl W.M., Staudt L.M. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011, 117:2396-2404.
3. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., Baer M.R., Holleran J.L., Egorin M.J., Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2009, 15:5250-5257.
4. Bantscheff M., Hopf C., Savitski M.M., Dittmann A., Grandi P., Michon A.M., Schlegl J., Abraham Y., Becher I., Bergamini G., Boesche M., Delling M., Dumpelfeld B., Eberhard D., Huthmacher C., Mathieson T., Poeckel D., Reader V., Strunk K., Sweetman G., Kruse U., Neubauer G., Ramsden N.G., Drewes G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 2011, 29:255-265.
5. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J.Clin. Oncol. 2005, 23:6333-6338.
6. Bliskovsky V., Ramsay E.S., Scott J., DuBois W., Shi W., Zhang S., Qian X., Lowy D.R., Mock B.A. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc. Natl. Acad. Sci. U S A 2003, 100:14982-14987.
7. Borisy A.A., Elliott P.J., Hurst N.W., Lee M.S., Lehar J., Price E.R., Serbedzija G., Zimmermann G.R., Foley M.A., Stockwell B.R., Keith C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U S A 2003, 100:7977-7982.
8. Broyl A., Hose D., Lokhorst H., de Knegt Y., Peeters J., Jauch A., Bertsch U., Buijs A., Stevens-Kroef M., Beverloo H.B., Vellenga E., Zweegman S., Kersten M.J., van der Holt B., el Jarari L., Mulligan G., Goldschmidt H., van Duin M., Sonneveld P. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010, 116:2543-2553.
9. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J.Clin. Invest. 2008, 118:3065-3074.
10. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
11. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
12. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., Sawyers C.L. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5:e8.
13. Dancey J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7:209-219.
14. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 2006, 5:649-659.
15. Day C.P., Carter J., Bonomi C., Esposito D., Crise B., Ortiz-Conde B., Hollingshead M., Merlino G. Lentivirus-mediated bifunctional cell labeling for invivo melanoma study. Pigment Cell Melanoma Res. 2009, 22:283-295.
16. de Boer C.J., Schuuring E., Dreef E., Peters G., Bartek J., Kluin P.M., van Krieken J.H. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995, 86:2715-2723.
17. Decaux O., Lode L., Magrangeas F., Charbonnel C., Gouraud W., Jezequel P., Attal M., Harousseau J.L., Moreau P., Bataille R., Campion L., Avet-Loiseau H., Minvielle S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J.Clin. Oncol. 2008, 26:4798-4805.
18. Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M. Characterization of MYC translocations in multiple myeloma cell lines. J.Nat. Cancer Ins. Monographs. 2008, 25-31.
19. Dilworth D., Liu L., Stewart A.K., Berenson J.R., Lassam N., Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 2000, 95:1869-1871.
20. Dong L.H., Cheng S., Zheng Z., Wang L., Shen Y., Shen Z.X., Chen S.J., Zhao W.L. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J.Hematol. Oncol. 2013, 6:53.
21. Federico M., Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J.Biomed. Biotechnol. 2011, 2011:475641.
22. Fernandez V., Hartmann E., Ott G., Campo E., Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J.Clin. Oncol. 2005, 23:6364-6369.
23. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., Kuehl W.M., Hernandez J.M., Minvielle S., Pilarski L.M., Shaughnessy J.D., Stewart A.K., Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004, 64:1546-1558.
24. Frost P., Moatamed F., Hoang B., Shi Y., Gera J., Yan H., Frost P., Gibbons J., Lichtenstein A. Invivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004, 104:4181-4187.
25. Gabrea A., Martelli M.L., Qi Y., Roschke A., Barlogie B., Shaughnessy J.D., Sawyer J.R., Kuehl W.M. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Gene. Chromosome. Cancer 2008, 47:573-590.
26. Gera J.F., Mellinghoff I.K., Shi Y., Rettig M.B., Tran C., Hsu J.H., Sawyers C.L., Lichtenstein A.K. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J.Biol. Chem. 2004, 279:2737-2746.
27. Giulino-Roth L., Wang K., MacDonald T.Y., Mathew S., Tam Y., Cronin M.T., Palmer G., Lucena-Silva N., Pedrosa F., Pedrosa M., Teruya-Feldstein J., Bhagat G., Alobeid B., Leoncini L., Bellan C., Rogena E., Pinkney K.A., Rubin M.A., Ribeiro R.C., Yelensky R., Tam W., Stephens P.J., Cesarman E. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012, 120:5181-5184.
28. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., Tidwell M.L., Greer J., Chung E.J., Lee M.J., Gore S.D., Sausville E.A., Zwiebel J., Karp J.E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109:2781-2790.
29. Gonzalez-Paz N., Chng W.J., McClure R.F., Blood E., Oken M.M., Van Ness B., James C.D., Kurtin P.J., Henderson K., Ahmann G.J., Gertz M., Lacy M., Dispenzieri A., Greipp P.R., Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109:1228-1232.
30. Gore L., Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2008, 14:4517-4525.
31. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
32. Gupta M., Ansell S.M., Novak A.J., Kumar S., Kaufmann S.H., Witzig T.E. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114:2926-2935.
33. Harvey R.D., Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 2007, 3:639-647.
34. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39:1388-1405.
35. Huang X., Wang S., Lee C.K., Yang X., Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 2011, 307:72-79.
36. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., Braggio E., Henry T., Zhu Y.X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J., Stewart A.K., Carpten J., Bergsagel P.L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
37. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
38. Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998, 91:1680-1687.
39. Kuehl W.M., Bergsagel P.L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J.Clin. Invest. 2012, 122:3456-3463.
40. Kummar S., Gutierrez M., Gardner E.R., Donovan E., Hwang K., Chung E.J., Lee M.J., Maynard K., Kalnitskiy M., Chen A., Melillo G., Ryan Q.C., Conley B., Figg W.D., Trepel J.B., Zwiebel J., Doroshow J.H., Murgo A.J. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 2007, 13:5411-5417.
41. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009, 19:R1046-R1052.
42. Lee C.K., Wang S., Huang X., Ryder J., Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010, 296:233-240.
43. Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Gene. Chromosome. Cancer 2007, 46:226-238.
44. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
45. McMillin D.W., Delmore J., Weisberg E., Negri J.M., Geer D.C., Klippel S., Mitsiades N., Schlossman R.L., Munshi N.C., Kung A.L., Griffin J.D., Richardson P.G., Anderson K.C., Mitsiades C.S. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 2010, 16:483-489.
46. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J.Clin. Oncol. 2009, 27:2278-2287.
47. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., Bailey C., Joseph M., Libermann T.A., Richon V.M., Marks P.A., Anderson K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. U S A 2004, 101:540-545.
48. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
49. Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011, 96:574-582.
50. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008, 22:2159-2168.
51. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
52. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
53. Pinyol M., Cobo F., Bea S., Jares P., Nayach I., Fernandez P.L., Montserrat E., Cardesa A., Campo E. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998, 91:2977-2984.
54. Rizzatti E.G., Falcao R.P., Panepucci R.A., Proto-Siqueira R., Anselmo-Lima W.T., Okamoto O.K., Zago M.A. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br. J. Haematol. 2005, 130:516-526.
55. Roecklein B.A., Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995, 85:997-1005.
56. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
57. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J., Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
58. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 2005, 4:1533-1540.
59. Stewart A.K. Novel therapies for relapsed myeloma. Hematol. Am. Soc. Hematol. Educ. Progr. 2009, 578-586.
60. Team R.D.C. R: A Language and Environment for Statistical Computing 2011.
61. Verheul H.M., Salumbides B., Van Erp K., Hammers H., Qian D.Z., Sanni T., Atadja P., Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res. 2008, 14:3589-3597.
62. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
63. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
64. Yazbeck V.Y., Buglio D., Georgakis G.V., Li Y., Iwado E., Romaguera J.E., Kondo S., Younes A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 2008, 36:443-450.
65. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burington B., Anaissie E., Hollmig K., Pineda-Roman M., Tricot G., van Rhee F., Walker R., Zangari M., Crowley J., Barlogie B., Shaughnessy J.D. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
66. Zhang S., Ramsay E.S., Mock B.A. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc. Natl. Acad. Sci. U S A 1998, 95:2429-2434.
67. Zhang S., Readinger J.A., DuBois W., Janka-Junttila M., Robinson R., Pruitt M., Bliskovsky V., Wu J.Z., Sakakibara K., Patel J., Parent C.A., Tessarollo L., Schwartzberg P.L., Mock B.A. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 2011, 117:1228-1238.
68. Zhang S.L., DuBois W., Ramsay E.S., Bliskovski V., Morse H.C., Taddesse-Heath L., Vass W.C., DePinho R.A., Mock B.A. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol. Cell. Biol. 2001, 21:310-318.
69. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.
70. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 2011, 12:21-35.